Moreover, the efficacy of savolitinib in combination with either gefitinib (31% PR, 16/51) or osimertinib (40% PR, 19/47) was demonstrated in patients with EGFR-mutant NSCLC with concurrent MET amplification after progression on first-line EGFR-TKI treatment (27). The gene discussed is MET; the disease is non-small cell lung carcinoma.